These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 17308261)
1. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Spina M; Simonelli C; Tirelli U J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261 [No Abstract] [Full Text] [Related]
2. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005 [TBL] [Abstract][Full Text] [Related]
3. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015 [TBL] [Abstract][Full Text] [Related]
4. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784 [TBL] [Abstract][Full Text] [Related]
5. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Italiano A; Jardin F; Peyrade F; Saudes L; Tilly H; Thyss A Haematologica; 2005 Sep; 90(9):1281-3. PubMed ID: 16154857 [TBL] [Abstract][Full Text] [Related]
6. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120 [TBL] [Abstract][Full Text] [Related]
8. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice]. van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131 [TBL] [Abstract][Full Text] [Related]
9. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy]. Korolenko VO; Gershanovich ML; Tikhonova VV Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764 [No Abstract] [Full Text] [Related]
10. [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]. Li YH; Jiang WQ; Huang HQ; Xu RH; Lin TY; Xia ZJ; He YJ; Guan ZZ Ai Zheng; 2003 Apr; 22(4):401-3. PubMed ID: 12703998 [TBL] [Abstract][Full Text] [Related]
11. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Kaplan LD; Lee JY; Ambinder RF; Sparano JA; Cesarman E; Chadburn A; Levine AM; Scadden DT Blood; 2005 Sep; 106(5):1538-43. PubMed ID: 15914552 [TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333 [TBL] [Abstract][Full Text] [Related]
13. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy]. Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040 [TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma. Gan H; Zhang F; Lin Y Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):397-9. PubMed ID: 12408775 [TBL] [Abstract][Full Text] [Related]
17. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV). Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627 [TBL] [Abstract][Full Text] [Related]
18. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Alliot C J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060 [No Abstract] [Full Text] [Related]
19. P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Tanaka PY; Calore EE Pathol Res Pract; 2007; 203(1):1-7. PubMed ID: 17157997 [TBL] [Abstract][Full Text] [Related]